サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1719131

クラミジア感染診断市場 - 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、感染症タイプ別、エンドユーザー別、地域別、競合別、2020年～2030年

Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type of Infections, By End User, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 184 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

クラミジア感染診断市場 - 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、感染症タイプ別、エンドユーザー別、地域別、競合別、2020年～2030年
出版日: 2025年04月30日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クラミジア感染診断の世界市場は、2024年に7億2,133万米ドルと評価され、2030年までには10億3,167万米ドルに達すると予測され、予測期間中のCAGRは6.12%で成長します。

クラミジア感染症の原因菌であるクラミジアトラコマティスは、世界的に最も普及している性感染症（STI）の原因の1つです。クラミジアは無症状であることが多いため、診断されないことが多く、不妊症、骨盤内炎症性疾患などの合併症を引き起こし、他の感染症にかかりやすくなります。STIに対する認識が高まり、特に15歳から24歳の性的に活発な人々の間でSTIの世界の負担が増加するにつれて、タイムリーで正確な診断に対する需要が高まっています。市場は、高感度で定評のある核酸増幅検査（NAAT）など、アクセス性と正確性を高める技術革新で対応してきました。集中型検査施設に依存しているにもかかわらず、現在進行中の取り組みでは、検査の納期を改善し、ポイント・オブ・ケア技術によって検査範囲を拡大することに重点を置いており、感染症を封じ込めるための広範な公衆衛生戦略を支援しています。

市場概要
予測期間 2026年～2030年
市場規模：2024年 7億2,133万米ドル
市場規模：2030年 10億3,167万米ドル
CAGR：2025年～2030年 6.12%
急成長セグメント 病院
最大市場 北米

主要な市場促進要因

クラミジア感染率の上昇がクラミジア感染診断市場を牽引

主要な市場課題

過小診断と認識不足

主要市場動向

技術の進歩

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のクラミジア感染診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 検査タイプ別（培養検査、核酸増幅検査（NAAT）、直接蛍光抗体検査、血清学的検査など）
    • 感染症タイプ別（性器クラミジア感染症、直腸クラミジア感染症、眼クラミジア感染症）
    • エンドユーザー別（病院、専門クリニック、診断センター）
    • 地域別
    • 企業別（2024ン絵）
  • 市場マップ
    • テストタイプ別
    • 感染症の種類別
    • エンドユーザー別
    • 地域別

第6章 北米のクラミジア感染診断市場展望

  • 市場規模・予測
  • 市場シェア・予測

第7章 欧州のクラミジア感染診断市場展望

  • 市場規模・予測
  • 市場シェア・予測

第8章 アジア太平洋のクラミジア感染診断市場展望

  • 市場規模・予測
  • 市場シェア・予測

第9章 南米のクラミジア感染診断市場展望

  • 市場規模・予測
  • 市場シェア・予測

第10章 中東・アフリカのクラミジア感染診断市場展望

  • 市場規模・予測
  • 市場シェア・予測

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 競合情勢

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 15821

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 million in 2024 and is projected to reach USD 1031.67 million by 2030, growing at a CAGR of 6.12% during the forecast period. Chlamydia trachomatis, the bacterium responsible for chlamydia infections, is one of the most widespread causes of sexually transmitted infections (STIs) globally. Due to its often asymptomatic nature, chlamydia frequently goes undiagnosed, leading to complications such as infertility, pelvic inflammatory disease, and increased vulnerability to other infections. As awareness grows and the global burden of STIs rises-particularly among sexually active individuals aged 15 to 24-demand for timely, accurate diagnostics has increased. The market has responded with technological innovations that enhance accessibility and accuracy, such as nucleic acid amplification tests (NAATs), which are recognized for their high sensitivity. Despite the reliance on centralized laboratories, ongoing efforts are focused on improving test turnaround and expanding reach through point-of-care technologies, supporting broader public health strategies to contain the infection.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 721.33 Million
Market Size 2030USD 1031.67 Million
CAGR 2025-20306.12%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

The increasing global incidence of chlamydia infections is a major force behind the growth of the diagnostics market. As one of the most commonly reported STIs worldwide, chlamydia poses a significant health risk-particularly among adolescents and young adults who often lack awareness or access to regular testing. The asymptomatic nature of the infection makes it difficult to detect early, increasing the likelihood of long-term reproductive health complications such as infertility and ectopic pregnancies. The heightened focus on routine screening, particularly in high-risk populations, has accelerated the demand for diagnostic tools capable of delivering rapid, accurate results. This has led to the development and deployment of innovative testing methods, bolstering early intervention efforts and supporting global STI control initiatives. Educational campaigns and increased testing infrastructure are further reinforcing the demand for reliable chlamydia diagnostic solutions.

Key Market Challenges

Underdiagnosis and Lack of Awareness

A persistent challenge in the chlamydia diagnostics market is the widespread underdiagnosis of the infection, largely due to its asymptomatic presentation in the majority of cases. Without noticeable symptoms, many individuals remain unaware they are infected and do not seek testing, allowing the disease to spread undetected. This issue is compounded by limited public knowledge about STI risks, as well as cultural stigma surrounding sexual health, which deters open discussion and testing. In some regions, inadequate healthcare infrastructure and insufficient provider emphasis on STI screening further restrict access to diagnostics. These systemic and societal barriers contribute to a gap between infection rates and testing volumes, limiting early treatment and increasing the burden of long-term health complications.

Key Market Trends

Technological Advancements

Advancements in molecular diagnostics are significantly shaping the chlamydia diagnostics market. NAATs, including PCR and LAMP, have become the benchmark for detecting the genetic material of Chlamydia trachomatis, offering unparalleled sensitivity and specificity. These methods enable early detection, which is critical for timely treatment and preventing transmission. Furthermore, smartphone-integrated diagnostic platforms are emerging as accessible, user-friendly tools that facilitate at-home testing. These innovations empower individuals to screen for STIs with greater privacy and convenience. In parallel, serological and antibody-based assays are being utilized to detect historical infections, contributing to epidemiological tracking and broader public health insights. The integration of nucleic acid and serological tests is enhancing diagnostic capability, paving the way for more comprehensive infection profiling and treatment planning.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type:

  • Culture Test
  • Nucleic Acid Amplification Test (NAAT)
  • Direct Fluorescent Antibody Test
  • Serology Test
  • Other

Chlamydia Infection Diagnostics Market, By Type of Infections:

  • Genital Chlamydia Infection
  • Rectal Chlamydia Infection
  • Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
    • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
    • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By Type of Infections
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Chlamydia Infection Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Type of Infections
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. United States Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Test Type
        • 6.2.4.1.2.2. By Type of Infections
        • 6.2.4.1.2.3. By End User
      • 6.2.4.2. Canada Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Test Type
        • 6.2.4.2.2.2. By Type of Infections
        • 6.2.4.2.2.3. By End User
      • 6.2.4.3. Mexico Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Test
        • 6.2.4.3.2.2. By Type of Infections
        • 6.2.4.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Type of Infections
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. France Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Test Type
        • 7.2.4.1.2.2. By Type of Infections
        • 7.2.4.1.2.3. By End User
      • 7.2.4.2. Germany Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Test Type
        • 7.2.4.2.2.2. By Type of Infections
        • 7.2.4.2.2.3. By End User
      • 7.2.4.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Test Type
        • 7.2.4.3.2.2. By Type of Infections
        • 7.2.4.3.2.3. By End User
      • 7.2.4.4. Italy Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Test Type
        • 7.2.4.4.2.2. By Type of Infections
        • 7.2.4.4.2.3. By End User
      • 7.2.4.5. Spain Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Test Type
        • 7.2.4.5.2.2. By Type of Infections
        • 7.2.4.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Type of Infections
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. China Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Test Type
        • 8.2.4.1.2.2. By Type of Infections
        • 8.2.4.1.2.3. By End User
      • 8.2.4.2. India Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Test Type
        • 8.2.4.2.2.2. By Type of Infections
        • 8.2.4.2.2.3. By End User
      • 8.2.4.3. South Korea Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Test Type
        • 8.2.4.3.2.2. By Type of Infections
        • 8.2.4.3.2.3. By End User
      • 8.2.4.4. Japan Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Test Type
        • 8.2.4.4.2.2. By Type of Infections
        • 8.2.4.4.2.3. By End User
      • 8.2.4.5. Australia Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Test Type
        • 8.2.4.5.2.2. By Type of Infections
        • 8.2.4.5.2.3. By End User

9. South America Chlamydia Infection Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Type of Infections
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Test Type
        • 9.2.4.1.2.2. By Type of Infections
        • 9.2.4.1.2.3. By End User
      • 9.2.4.2. Argentina Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Test Type
        • 9.2.4.2.2.2. By Type of Infections
        • 9.2.4.2.2.3. By End User
      • 9.2.4.3. Colombia Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Test Type
        • 9.2.4.3.2.2. By Type of Infections
        • 9.2.4.3.2.3. By End User

10. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Type of Infections
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Test Type
        • 10.2.4.1.2.2. By Type of Infections
        • 10.2.4.1.2.3. By End User
      • 10.2.4.2. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Test Type
        • 10.2.4.2.2.2. By Type of Infections
        • 10.2.4.2.2.3. By End User
      • 10.2.4.3. UAE Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Test Type
        • 10.2.4.3.2.2. By Type of Infections
        • 10.2.4.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. F. Hoffmann-La Roche Ltd.
  • 13.2. Abbott Laboratories
  • 13.3. Hologic, Inc.
  • 13.4. Becton, Dickinson and Company
  • 13.5. Bio-Rad Laboratories, Inc
  • 13.6. Quidel Corporation
  • 13.7. DiaSorin SpA
  • 13.8. AstraZeneca
  • 13.9. Teva Pharmaceutical Industries Limited
  • 13.10. bioMerieux SA

14. Strategic Recommendations

15. About us & Disclaimer